Health Condition 1: N944- Primary dysmenorrhea
Conditions
Interventions
Intervention1: Tablet Asaroon: 3 tablets of 500mg each, twice daily orally for 3 days in 2 consecutive menstrual cycles
Control Intervention1: Tablet Mefenamic acid: 1 tablet of 500mg twice daily oral
Sponsors
Luqman Unani Medical College Hospital and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Married and unmarried patients between 15 to 35 years of ages having regular menstrual cycles Patient diagnosed with primary dysmenorrhea Patients with Visual Analog Scale less than or equal to 4cm for at least three menstrual cycles before this study
Exclusion criteria
Exclusion criteria: Pelvic disease such as fibroid adenomyosis PID endometrial polyp ovarian tumour Irregular menstrual cycles Pregnancy and lactation Systemic illness Oral contraceptives and those Wearing IUCD devices Participants with congenital anomalies of uterus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Severity of pain determined by VAS Change in duration of menstrual painTimepoint: before after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in HRQoL determined by SF-12 v1 health survey questionnaire Change in PBLAC score for menstrual blood lossTimepoint: before after treatment | — |
Countries
India
Contacts
Public ContactDr Nikhat Kausar Inamdar
Luqman Unani Medical College Hospital and Research Centre
Outcome results
None listed